Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Over time, GeneDx plans to expand into newborn screening, a potentially $10 billion marketthen eventually into adult screening to replace multi-gene panel and individual gene tests, a future market pegged at $16 billion, Katherine Stueland, GeneDxs president and CEO, told GEN Edge last month With tougher comps in 25 and a potential headwind to revenues emerging in HCT, it is harder to argue for multiple expansion from here, Peterson said
GSTM3 reverses the resistance of hepatoma cells to radiation by regulating the expression of cell cycle/apoptosis-related molecules
Ethics declarations Competing interests KGW and VJNB are co-founders and shareholders of Aprea Therapeutics AB, a company that develops novel p53-based cancer therapy
The 1mg cohort was a single-step initiation (dosed at 1mg/week throughout without escalation), and a single 10mg vial covers the entire 10-week 1mg cohort schedule
So why is this happening
Portions naturally decrease
